NTRK1 and metastatic colorectal cancer: Additionally, LMNA-NTRK1-positive patients with metastatic colorectal cancer showed a remarkable response to Entrectinib, followed by resistance to Entrectinib mediated by NTRK1 G595R and G667C mutations and these mutations also showed immense resistance to Larotrectinib and TSR-011 [158].